Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Rapid Acceleration of Diagnostics - TECH (RADx-TECH): Self-Testing for Our Protection from COVID-19 (STOP COVID-19)

ABSTRACT: Rapid Acceleration of Diagnostics - TECH (RADx-TECH): Self-Testing for Our Protection from COVID-19 (STOP COVID-19)

PROVIDER: PRJNA948124 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Rapid Acceleration of Diagnostics - TECH (RADx-TECH): RADx Tech COVID-19 Viral Dynamics/COVID Detect

Project description:Rapid Acceleration of Diagnostics - TECH (RADx-TECH): RADx Tech COVID-19 Viral Dynamics/COVID Detect

| PRJNA998942 | ENA

Rapid Acceleration of Diagnostics - TECH (RADx-TECH): RADx Tech COVID-19 Viral Dynamics/COVID Detect

Project description:Rapid Acceleration of Diagnostics - TECH (RADx-TECH): RADx Tech COVID-19 Viral Dynamics/COVID Detect

| PRJNA998977 | ENA

Rapid Acceleration of Diagnostics - TECH (RADx-TECH): COVID-19 Test At Home Efficacy Sub-Study

Project description:Rapid Acceleration of Diagnostics - TECH (RADx-TECH): COVID-19 Test At Home Efficacy Sub-Study

| PRJNA869820 | ENA

Rapid Acceleration of Diagnostics - TECH(RADx-TECH): COVID-19 Test At Home Feasibility Sub-Study

Project description:Rapid Acceleration of Diagnostics - TECH(RADx-TECH): COVID-19 Test At Home Feasibility Sub-Study

| PRJNA789640 | ENA

Rapid Acceleration of Diagnostics - TECH (RADx-TECH): COVID-19 Test At Home Efficacy Sub-Study

Project description:Rapid Acceleration of Diagnostics - TECH (RADx-TECH): COVID-19 Test At Home Efficacy Sub-Study

| PRJNA869821 | ENA

Rapid Acceleration of Diagnostics - TECH(RADx-TECH): COVID-19 Test At Home Feasibility Sub-Study

Project description:Rapid Acceleration of Diagnostics - TECH(RADx-TECH): COVID-19 Test At Home Feasibility Sub-Study

| PRJNA789641 | ENA

Rapid Acceleration of Diagnostics - Underserved Populations (RADx-UP): Safety, Testing/Transmission and Outcomes in Pregnancies with COVID-19 (STOP COVID-19)

Project description:Rapid Acceleration of Diagnostics - Underserved Populations (RADx-UP): Safety, Testing/Transmission and Outcomes in Pregnancies with COVID-19 (STOP COVID-19)

| PRJNA835580 | ENA

Rapid Acceleration of Diagnostics - Underserved Populations (RADx-UP): Safety, Testing/Transmission and Outcomes in Pregnancies with COVID-19 (STOP COVID-19)

Project description:Rapid Acceleration of Diagnostics - Underserved Populations (RADx-UP): Safety, Testing/Transmission and Outcomes in Pregnancies with COVID-19 (STOP COVID-19)

| PRJNA835581 | ENA

Multiple Early Factors Anticipate Post-Acute COVID-19 Sequelae

Project description:Post-acute sequelae of COVID-19 (PASC) represent an emerging global crisis. However, quantifiable risk-factors for PASC and their biological associations are poorly resolved. We executed a deep multi-omic, longitudinal investigation of 309 COVID-19 patients from initial diagnosis to convalescence (2-3 months later), integrated with clinical data, and patient-reported symptoms. We resolved four PASC-anticipating risk factors at the time of initial COVID-19 diagnosis: type 2 diabetes, SARS-CoV-2 RNAemia, Epstein-Barr virus viremia, and specific autoantibodies. In patients with gastrointestinal PASC, SARS-CoV-2-specific and CMV-specific CD8+ T cells exhibited unique dynamics during recovery from COVID-19. Analysis of symptom-associated immunological signatures revealed coordinated immunity polarization into four endotypes exhibiting divergent acute severity and PASC. We find that immunological associations between PASC factors diminish over time leading to distinct convalescent immune states. Detectability of most PASC factors at COVID-19 diagnosis emphasizes the importance of early disease measurements for understanding emergent chronic conditions and suggests PASC treatment strategies.

2022-02-01 | E-MTAB-10129 | biostudies-arrayexpress

Unresolved Immune Dysfunction is Lethal in Both COVID-19 and non-COVID-19 Sepsis

Project description:In this prospective observational cohort study, we found transcriptional evidence that persistent immune dysfunction was associated with 28-day mortality in both COVID-19 and non-COVID-19 septic patients. COVID-19 patients had an early antiviral response but became indistinguishable on a gene expression level from non-COVID-19 sepsis patients a week later. Early treatment of COVID-19 and non-COVID-19 sepsis ICU patients should focus on pathogen control, but both patient groups also require novel immunomodulatory treatments, particularly later during ICU hospitalization, independent of admission diagnosis. Some T1 samples were uploaded in GSE185263 and were not re-uploaded in this series.

2023-03-24 | GSE222393 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data